SARCLISA Drug Profile

Summary for Tradename: SARCLISA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for SARCLISA

Recent Clinical Trials for SARCLISA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Assistance Publique - Hpitaux de Paris	PHASE2
Deutsche Studiengruppe Multiples Myelom (DSMM)	Phase 3
University of Heidelberg Medical Center	Phase 3

See all SARCLISA clinical trials

Pharmacology for SARCLISA

Mechanism of Action	CD38-directed Antibody Interactions
Established Pharmacologic Class	CD38-directed Cytolytic Antibody
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SARCLISA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SARCLISA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for SARCLISA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	SARCLISA	isatuximab-irfc	Injection	761113		2036-10-04	Patent claims search
Sanofi-aventis U.s. Llc	SARCLISA	isatuximab-irfc	Injection	761113		2037-07-20	Patent claims search
Sanofi-aventis U.s. Llc	SARCLISA	isatuximab-irfc	Injection	761113		2036-02-23	Patent claims search
Sanofi-aventis U.s. Llc	SARCLISA	isatuximab-irfc	Injection	761113		2038-08-10	Patent claims search
Sanofi-aventis U.s. Llc	SARCLISA	isatuximab-irfc	Injection	761113		2039-09-19	Patent claims search
Sanofi-aventis U.s. Llc	SARCLISA	isatuximab-irfc	Injection	761113		2039-02-01	Patent claims search
Sanofi-aventis U.s. Llc	SARCLISA	isatuximab-irfc	Injection	761113		2036-07-01	Patent claims search

Market Dynamics and Financial Trajectory for SARCLISA

Last updated: February 19, 2026

What is SARCLISA?

SARCLISA (isatuximab-irfc) is a monoclonal antibody developed by Sanofi targeting CD38, approved for relapsed/refractory multiple myeloma. It received FDA approval on March 27, 2020, as part of combination therapy. SARCLISA is positioned within the immune-oncology segment, competing primarily with drugs like daratumumab (Darzalex) and isatuximab's sister molecule, Darzalex.

Market Size and Growth Drivers

Multiple Myeloma Market

• Estimated global multiple myeloma (MM) market was USD 16.9 billion in 2022.
• Projected compound annual growth rate (CAGR): 10.2% through 2028.
• Growth driven by increasing incidence, advancements in treatment regimens, and expanding indications for monoclonal antibodies like SARCLISA.

Therapeutic Competition

• Daratumumab dominates with over 70% market share among CD38 antibodies.
• SARCLISA's market penetration hinges on efficacy, safety profile, and differentiation from competitors.

Key Factors Influencing Market Dynamics

1. Clinical Efficacy and Safety: SARCLISA has demonstrated comparable or superior progression-free survival (PFS) in combination settings versus competitors.
2. Regulatory Approvals and Indications: Expanded approvals for earlier lines of therapy, including maintenance and newly diagnosed MM, drive valuation.
3. Pricing and Reimbursement: Average sales prices for monoclonal antibodies range USD 9,000–10,000 per dose. Reimbursement policies influence adoption rates.
4. Patient Access Programs: Pharmaceutical companies' efforts to expand access impact sales volumes.

Revenue Trajectory and Financial Performance

Recent Sales Figures

• In the full year 2022, SARCLISA generated approximately USD 430 million in worldwide sales.
• Compared to USD 273 million in 2021, reflecting rapid growth.

Revenue Breakdown

Year	Sales (USD millions)	Growth Rate	Key Markets
2020	150	N/A	US primarily
2021	273	82%	US, EU
2022	430	57%	US (60%), EU (20%), rest (20%)

Profitability Considerations

• Gross margins estimated at 65%-70%, typical for biotech monoclonal antibodies.
• Operating expenses include R&D (20% of sales), sales, marketing, and distribution.
• Net margins remain narrow due to high R&D costs and competitive pricing pressures.

Future Market Outlook

R&D and Line Extensions

• Ongoing trials for SARCLISA in early-line MM, targeted therapies, and combination regimens.
• Anticipated label expansions could drive sales beyond current indications.

Geographical Expansion

• Increasing penetration in Asia-Pacific, Latin America, and Eastern Europe.
• Partnerships with local distributors and payers aimed at broadening access.

Pricing and Market Share Projections

• Modeling suggests a potential USD 1.2 billion in annual sales by 2027 if expansion targets are met.
• Market share could reach 25-30% of the CD38 antibody segment, provided competitive and regulatory hurdles are managed.

Risks and Challenges

• High competition from established drugs like Darzalex and newer agents.
• Authorizations for biosimilars could pressure pricing and margins.
• Clinical trial outcomes significantly influence future market share.

Key Takeaways

• SARCLISA's revenue growth reflects successful market penetration, driven by expanded indications and combination therapies.
• Competition remains fierce; positioning relies on clinical efficacy and market access.
• The global MM therapeutics market is expanding at a double-digit CAGR, supporting future revenue upside.
• Clinical and regulatory advancements are critical for sustainable growth.
• Pricing pressures and biosimilar entries pose ongoing threats to profitability.

FAQs

1. What factors determine SARCLISA's market share?

Efficacy in combination regimens, safety profile, regulatory approvals, pricing strategies, and patient access programs. Competitor activity and biosimilar entries also influence market share.

2. How significant are biosimilars for SARCLISA's future?

Biosimilars for CD38 antibodies are under development, potentially reducing market prices and affecting sales volume unless SARCLISA gains distinct advantages or expands indications.

3. What is the expected timeline for SARCLISA's label expansion?

Clinical trial results for early-line and other indications are expected over 2023-2025. Regulatory approvals could follow within 12-24 months post-trial completion.

4. How does SARCLISA compare financially to competitors?

While recent sales growth is strong, profitability margins are narrower than some competitors due to market penetration costs and pricing pressures. Long-term assumes successful expansion and differentiated positioning.

5. What are the main risks impacting SARCLISA's financial outlook?

Intensified competition, biosimilar development, delayed trial results, regulatory hurdles, and pricing pressures threaten the revenue trajectory.

---

Sources:

[1] MarketWatch. (2023). Multiple Myeloma Market Size and Forecast.
[2] Sanofi. (2023). SARCLISA (isatuximab) product pipeline and financials.
[3] Evaluate Pharma. (2023). Oncology Biotech Financials and Market Trends.